Compare SLDB & ICFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLDB | ICFI |
|---|---|---|
| Founded | 2013 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2017 | 2006 |
| Metric | SLDB | ICFI |
|---|---|---|
| Price | $9.55 | $77.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 4 |
| Target Price | $16.36 | ★ $99.25 |
| AVG Volume (30 Days) | ★ 2.6M | 287.3K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.82% |
| EPS Growth | ★ 34.97 | N/A |
| EPS | N/A | ★ 1.12 |
| Revenue | $8,094,000.00 | ★ $1,229,162,000.00 |
| Revenue This Year | N/A | $4.12 |
| Revenue Next Year | N/A | $5.33 |
| P/E Ratio | ★ N/A | $68.04 |
| Revenue Growth | N/A | ★ 3.72 |
| 52 Week Low | $3.79 | $58.83 |
| 52 Week High | $11.45 | $101.71 |
| Indicator | SLDB | ICFI |
|---|---|---|
| Relative Strength Index (RSI) | 54.10 | 59.88 |
| Support Level | $6.38 | $73.89 |
| Resistance Level | $11.45 | $82.78 |
| Average True Range (ATR) | 0.68 | 3.20 |
| MACD | -0.12 | 0.45 |
| Stochastic Oscillator | 32.02 | 80.38 |
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
ICF International Inc provides professional services and technology-based solutions, including management, technology and policy consulting and implementation services, to government and commercial clients in the U.S. and internationally. Its government clients include U.S. federal agencies, state and local governments and international governments, as well as commercial clients inside and outside the U.S. It supports clients in Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs; and Security and Other Civilian and Commercial markets. The company delivers services across the life cycle of a policy, program or project through Advisory Services, Program Implementation, Analytics Services, Digital Services and Engagement Services.